Israel-Medical-Healthcare

[genisi]

Results from phase II of CF101 for RA were puzzling:
For one endpoint the placebo effect was similar to that of the drug. However, 3 other parameters looked positive for the drug.
What they are probably doing now is a full report of the trial, and letting reviewers go over their numbers and side effects.
Due to the good safety profile of the drug, my guess is that they can convince the FDA to let them go to phase III, but they will need a partner and with the excipient issue, they may have a hard time finding one. I would be very cautious about CF101 future for RA.